SPOTLIGHT -
Phillip H. Kuo, MD, PhD, Assesses Use of 177Lu-PSMA-617 in a Multidisciplinary Setting for Pretreated mCRPC
Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.
Phillip H. Kuo, MD, PhD, Evaluates Future Research Surrounding PSMA-PET Parameters and Response to 177Lu-PSMA-617 in mCRPC
Phillip H. Kuo, MD, PhD, spoke about the future of theragnostic imaging in patients with metastatic castration-resistant prostate cancer.
Phillip H. Kuo, MD, PhD, Examines Utility of PSMA-PET Parameters to Predict Response to 177Lu-PSMA-617 in mCRPC
Phillip H. Kuo, MD, PhD, spoke about how prostate-specific membrane antigen PET scan testing affected outcomes in patients with metastatic castration-resistant prostate cancer.
Phillip H. Kuo, MD, PhD, Reviews Rationale of Phase 3 VISION Trial of 177Lu-PSMA-617 in mCRPC
Phillip H. Kuo, MD, PhD, spoke about the use of theragnostic treatment and imaging for patients with metastatic castration-resistant prostate cancer.
